FDA Commissioner Marty Makary resigns; Kyle Diamantas named acting commissioner
FDA Commissioner Marty Makary has resigned after months of internal turmoil, and Kyle Diamantas, the agency's top food regulator, is stepping in as acting commissioner, raising questions about continuity on drug decisions [1].
Food and Drug Administration Commissioner Marty Makary is resigning, and Kyle Diamantas, who has served as the agency's top food official, will take over as acting commissioner [1]. President Donald Trump confirmed the resignation while answering reporters' questions ahead of a trip to China, telling them Makary "was having some difficulty" and calling him "a great doctor" who would "go on and lead a good life" [1].
According to reporting on the departure, Makary's tenure at the FDA was marked by staff turnover and controversy, including disputes over political pressure on the agency [1]. The move makes Makary the latest senior Trump administration health official to leave, adding another vacancy inside the Department of Health and Human Services under Secretary Robert F. Kennedy Jr. [1].
Diamantas previously held the title of Deputy Commissioner for Food at the FDA before being named acting commissioner [1]. The available reporting does not lay out a timeline for a permanent replacement, and it does not describe how Diamantas plans to run the agency's drug-review or enforcement work in the meantime [1].
Why it matters for patients
The FDA commissioner oversees the agency that approves new GLP-1 medicines, sets rules for compounded versions sold outside the brand-name supply chain, and decides how the agency responds to shortages and safety signals. A change in leadership at the top of the agency can affect how quickly pending matters move and how consistently policy is applied, but the sourcing available here does not describe any specific effect on semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), or orforglipron (Foundayo) programs [1].
Patients currently taking or considering a GLP-1 medicine will not see an immediate change because of a leadership transition alone. Decisions on drug applications, labeling, and compounding policy are made by career staff and specialized offices within the FDA, and the commissioner's office sits above that day-to-day work. Still, an acting commissioner brings some uncertainty about priorities, staffing, and how fast open questions move through the agency, none of which is detailed in the source available for this story [1].
It is not yet known, based on the reporting reviewed here, whether this transition will affect the timing of any pending FDA actions related to GLP-1 drugs, including matters involving high-dose formulations or the list of bulk drug substances that outsourcing compounding pharmacies, known as 503B facilities, are allowed to use. Readers should treat any claims about specific GLP-1 policy effects from this leadership change as unconfirmed until the FDA or credible reporting addresses them directly.
What happens next
Diamantas is now acting commissioner, but the source reviewed for this story does not specify how long an acting arrangement is expected to last or when the Trump administration might nominate a permanent successor [1]. Trump's public comments, made just before departing for a trip to China, did not include a timeline for naming a new commissioner or details on who else might be considered for the post [1]. Semaglutides.org will continue tracking FDA actions on GLP-1 medicines as agency leadership changes unfold.
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.